

Recro Pharma Inc

CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 08-Feb-2015

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)



ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 6

Product Portfolio Drug Pipeline Detail..... 9

 Phase 2 Clinical..... 10

 Phase 1 Clinical..... 31

[Return to Table of Contents](#)

Recro Pharma Inc

COMPANY OVERVIEW

Company Name	Recro Pharma Inc
Parent Company Name	Recro Pharma Inc
Website	http://www.recropharma.com/
Country	US
Number of Drugs in Active Development	5
Number of Inactive Drugs	1
Number of Patents as Owner	3
Number of Patents as Third Party	0
Number of Deals	2
Key Indications	Pain,Neuropathic pain,Myalgia,Neuropathy,Neuritis,Cancer pain,Headache,Hyperalgesia,Hypotension,Lower back pain,Migraine,Shock
Key Target-based Actions	Alpha 2 adrenoceptor agonist
Key Technologies	Small molecule therapeutic,Transdermal formulation,Buccal formulation systemic,Nasal formulation,Buccal formulation local,Intrathecal formulation,Systemic formulation unspecified

COMPANY PROFILE

SUMMARY

Recro Pharma Inc is a specialty pharmaceutical company which develops therapeutics for the potential adjunctive management and treatment of serious pain and related conditions.

FINANCIAL

In February 2015, Recro Pharma entered into a common stock purchase agreement with Aspire Capital Fund. Under the new agreement, Recro had the right to sell up to \$10 million in shares of common stock to Aspire Capital over a two-year period.

In June 2014, Recro Pharma was added to the Russell Microcap Index.

In March 2014, Recro Pharma priced its IPO of 3,750,000 shares of common stock at \$8.00 per share for an expected gross proceeds of \$30 million. At that time, underwriters were to be granted a 45-day option to purchase up to 562,500 additional shares. The stock was to be traded on the NASDAQ Capital Market under the symbol 'REPH'; at that time, the offering was to close on March 12, 2014. Later that month, the company raised gross proceeds of \$34,500,000 with the full exercise of the over-allotment option.


[Return to Table of Contents](#)

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Neurological disease	5	1	6

[Return to Table of Contents](#)

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	4
Phase 1 Clinical	1
No Development Reported	1

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Patent - Exclusive Rights	0	0	1	0	1
Drug - Development/Commercialization License	0	0	1	0	1

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Neurological disease	1	4

[Return to Table of Contents](#)

Trials by Phase

Phase	Ongoing	All
Phase 2	1	3
Phase 1	0	1

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

Indication	As Owner	As Third Party	Total
Cardiovascular disease	1	0	1
Musculoskeletal disease	3	0	3
Neurological disease	3	0	3
Inflammatory disease	2	0	2

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)



PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

dexmedetomidine (sublingual, pain), Recro Pharma

dexmedetomidine (sublingual, pain), Recro Pharma SNAPSHOT

Drug Name	dexmedetomidine (sublingual, pain), Recro Pharma
Key Synonyms	dexmedetomidine
Originator Company	Recro Pharma Inc
Active Companies	Recro Pharma Inc
Inactive Companies	
Highest Status	Phase 2 Clinical
Active Indications	Pain
Target-based Actions	Alpha 2 adrenoceptor agonist
Other Actions	Analgesic
Technologies	Buccal formulation systemic;Small molecule therapeutic
Last Change Date	21-May-2013

dexmedetomidine (sublingual, pain), Recro Pharma DEVELOPMENT PROFILE

SUMMARY

Recro Pharma is developing RP-1108 (DEX-SL, presumed to be RP-1100), a sublingual formulation of the alpha 2 agonist dexmedetomidine licensed from Orion, for the potential treatment of breakthrough pain,. By December 2011, phase II development was underway. In March 2012, the company was planning to complete development by late 2013 and expected to launch the drug by late 2014 or early 2015. In May 2013, the drug was listed as being in phase II development. At that time, the company anticipated a section 505(b)(2) regulatory strategy for the drug and planned on seeking to outlicense the drug in Europe, Turkey and the Commonwealth of Independent States.


dexmedetomidine (sublingual, pain), Recro Pharma DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Recro Pharma Inc	Pain	US	Phase 2 Clinical	06-Dec-2011

dexmedetomidine (sublingual, pain), Recro Pharma CHEMICAL STRUCTURES

[Return to Table of Contents](#)

CAS Registry Number:	Confidence Level:
113775-47-6	1
	
Name	Type
dexmedetomidine	INN
MPV-1440	Research Code
DEX-SL	Research Code
DEX-IN	Research Code
DEX-TD	Research Code

dexmedetomidine (sublingual, pain), Recro Pharma DRUG NAMES

Names	Type
dexmedetomidine (sublingual, pain), Recro Pharma	
DEX-SL	Research Code
dexmedetomidine	INN
RP-1100	Research Code
RP-1108	Research Code

dexmedetomidine (sublingual, pain), Recro Pharma CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Lower back pain											
0	0	0	0	0	0	0	1	0	0	0	1

[Return to Table of Contents](#)

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	0	1	0	0	0	1

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

dexmedetomidine (sublingual, pain), Recro Pharma DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Recro Pharma Inc	0	0	1	0	1
Orion Corp	1	0	0	0	1

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Patent - Exclusive Rights	1	0	1

PATENTS


Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Recro Pharma Inc	1	0	1

Patents by Drug Relationship Type Chart



[Return to Table of Contents](#)

Patents by Drug Relationship Type Table

Drug Relationship	Total
Product	1

fadolmidine (intrathecal formulation, pain), Recro Pharma

fadolmidine (intrathecal formulation, pain), Recro Pharma SNAPSHOT

Drug Name	fadolmidine (intrathecal formulation, pain), Recro Pharma
Key Synonyms	fadolmidine
Originator Company	Recro Pharma Inc
Active Companies	Recro Pharma Inc
Inactive Companies	
Highest Status	Phase 2 Clinical
Active Indications	Pain
Target-based Actions	Alpha 2 adrenoceptor agonist
Other Actions	Analgesic
Technologies	Small molecule therapeutic;Intrathecal formulation
Last Change Date	21-May-2013

fadolmidine (intrathecal formulation, pain), Recro Pharma DEVELOPMENT PROFILE

SUMMARY

Recro Pharma is developing FADO-IT, an intrathecal formulation of the alpha 2 agonist fadolmidine, for the potential treatment of pain. In May 2013, the drug was listed as being in phase II development.


fadolmidine (intrathecal formulation, pain), Recro Pharma DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Recro Pharma Inc	Pain	US	Phase 2 Clinical	14-May-2013

fadolmidine (intrathecal formulation, pain), Recro Pharma CHEMICAL STRUCTURES

[Return to Table of Contents](#)

CAS Registry Number:	Confidence Level:
189353-31-9	1
	
Name	Type
fadolmidine	INN

fadolmidine (intrathecal formulation, pain), Recro Pharma DRUG NAMES

Names	Type
fadolmidine (intrathecal formulation, pain), Recro Pharma	
FADO-IT	Research Code
fadolmidine	INN

fadolmidine (intrathecal formulation, pain), Recro Pharma CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Pain											
0	0	0	0	0	1	0	0	0	0	0	1

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	1	0	0	0	0	0	1

Phase Definitions

[Return to Table of Contents](#)

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

fadolmidine (intrathecal formulation, pain), Recro Pharma DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Recro Pharma Inc	0	0	1	0	1
Orion Corp	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

dexmedetomidine (transdermal formulation, pain), Recro Pharma

dexmedetomidine (transdermal formulation, pain), Recro Pharma SNAPSHOT

Drug Name	dexmedetomidine (transdermal formulation, pain), Recro Pharma
Key Synonyms	dexmedetomidine
Originator Company	Recro Pharma Inc
Active Companies	Recro Pharma Inc
Inactive Companies	
Highest Status	Phase 2 Clinical
Active Indications	Pain
Target-based Actions	Alpha 2 adrenoceptor agonist
Other Actions	Analgesic
Technologies	Small molecule therapeutic;Transdermal formulation
Last Change Date	21-May-2013

dexmedetomidine (transdermal formulation, pain), Recro Pharma DEVELOPMENT PROFILE

SUMMARY

Recro Pharma is developing RP-1008 (DEX-TD), a transdermal formulation of the alpha 2 agonist dexmedetomidine licensed from Orion, for the potential adjunctive management of severe, intractable pain including cancer pain. In May 2013, the drug was listed as being in phase II development. At that time, the company anticipated a section 505(b)(2) regulatory strategy for the drug and planned on seeking to outlicense the drug in Europe, Turkey and the Commonwealth of Independent States.


dexmedetomidine (transdermal formulation, pain), Recro Pharma DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Recro Pharma Inc	Pain	US	Phase 2 Clinical	14-May-2013

dexmedetomidine (transdermal formulation, pain), Recro Pharma CHEMICAL STRUCTURES

[Return to Table of Contents](#)

CAS Registry Number:	Confidence Level:
113775-47-6	1
	
Name	Type
dexmedetomidine	INN
DEX-TD	Research Code
DEX-SL	Research Code
MPV-1440	Research Code
DEX-IN	Research Code


dexmedetomidine (transdermal formulation, pain), Recro Pharma DRUG NAMES

Names	Type
RP-1008	Research Code
DEX-TD	Research Code
dexmedetomidine	INN
dexmedetomidine (transdermal formulation, pain), Recro Pharma	

[Return to Table of Contents](#)

DEALS

Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Orion Corp	1	0	0	0	1
Recro Pharma Inc	0	0	1	0	1

[Return to Table of Contents](#)

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Patent - Exclusive Rights	1	0	1

PATENTS


Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Recro Pharma Inc	1	0	1

Patents by Drug Relationship Type Chart



[Return to Table of Contents](#)

Patents by Drug Relationship Type Table

Drug Relationship	Total
Formulation	1

dexmedetomidine (intranasal, pain), Recro Pharma

dexmedetomidine (intranasal, pain), Recro Pharma SNAPSHOT

Drug Name	dexmedetomidine (intranasal, pain), Recro Pharma
Key Synonyms	
Originator Company	Recro Pharma Inc
Active Companies	Recro Pharma Inc
Inactive Companies	
Highest Status	Phase 2 Clinical
Active Indications	Pain
Target-based Actions	Alpha 2 adrenoceptor agonist
Other Actions	Analgesic
Technologies	Small molecule therapeutic;Systemic formulation unspecified;Nasal formulation
Last Change Date	30-Oct-2014

dexmedetomidine (intranasal, pain), Recro Pharma DEVELOPMENT PROFILE

SUMMARY

Recro Pharma is developing Dex-IN, an intranasal formulation of the alpha 2 agonist dexmedetomidine licensed from Orion, for the potential intranasal treatment of breakthrough pain including cancer pain,. In May 2013, the drug was listed as being in phase II development . In June 2014, a phase IIb trial was initiated . In September 2014, the company planned to initiate a revised trial in fourth quarter of 2014 and top-line data were expected by mid-2015. In October 2014, further data from the trial were reported. In May 2013, the company planned on seeking to outlicense the drug in Europe, Turkey and the Commonwealth of Independent States.

dexmedetomidine (intranasal, pain), Recro Pharma DEVELOPMENT STATUS


CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Recro Pharma Inc	Pain	US	Phase 2 Clinical	14-May-2013

dexmedetomidine (intranasal, pain), Recro Pharma CHEMICAL STRUCTURES

[Return to Table of Contents](#)



CAS Registry Number:	Confidence Level:
113775-47-6	1
	
Name	Type
dexmedetomidine	INN
MPV-1440	Research Code
DEX-TD	Research Code
DEX-IN	Research Code
DEX-SL	Research Code

dexmedetomidine (intranasal, pain), Recro Pharma DRUG NAMES

Names	Type
dexmedetomidine (intranasal, pain), Recro Pharma	
DEX-IN	Research Code

dexmedetomidine (intranasal, pain), Recro Pharma CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Pain											
0	0	0	0	1	2	0	0	0	0	1	2

[Return to Table of Contents](#)

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	1	2	0	0	0	0	1	2

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

dexmedetomidine (intranasal, pain), Recro Pharma DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



[Return to Table of Contents](#)

Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Recro Pharma Inc	0	0	1	0	1
Orion Corp	1	0	0	0	1

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Patent - Exclusive Rights	1	0	1

PATENTS


Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Recro Pharma Inc	1	0	1

Patents by Drug Relationship Type Chart



[Return to Table of Contents](#)

Patents by Drug Relationship Type Table

Drug Relationship	Total
Formulation	1

[Return to Table of Contents](#)

fadolmidine (topical, neuropathic pain), Recro Pharma

fadolmidine (topical, neuropathic pain), Recro Pharma SNAPSHOT

Drug Name	fadolmidine (topical, neuropathic pain), Recro Pharma
Key Synonyms	fadolmidine
Originator Company	Recro Pharma Inc
Active Companies	Recro Pharma Inc
Inactive Companies	
Highest Status	Phase 1 Clinical
Active Indications	Neuropathic pain
Target-based Actions	Alpha 2 adrenoceptor agonist
Other Actions	Analgesic
Technologies	Small molecule therapeutic;Transdermal formulation
Last Change Date	17-May-2013

fadolmidine (topical, neuropathic pain), Recro Pharma DEVELOPMENT PROFILE

SUMMARY

Recro Pharma is developing FADO-TP, a topical formulation of the alpha 2 agonist fadolmidine, for the potential treatment of pain associated with regional neuropathies. In May 2013, the drug was listed as being in phase I development. At that time, the company planned on seeking to outlicense the drug in Europe, Turkey and the Commonwealth of Independent States.

fadolmidine (topical, neuropathic pain), Recro Pharma DEVELOPMENT STATUS


CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Recro Pharma Inc	Neuropathic pain	US	Phase 1 Clinical	14-May-2013

fadolmidine (topical, neuropathic pain), Recro Pharma CHEMICAL STRUCTURES

[Return to Table of Contents](#)



CAS Registry Number:	Confidence Level:
189353-31-9	1
	
Name	Type
fadolmidine	INN


fadolmidine (topical, neuropathic pain), Recro Pharma DRUG NAMES

Names	Type
fadolmidine (topical, neuropathic pain), Recro Pharma	
FADO-TP	Research Code
fadolmidine	INN

[Return to Table of Contents](#)

DEALS


Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Orion Corp	1	0	0	0	1
Recro Pharma Inc	0	0	1	0	1

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

